CURIS INC (CRIS) Stock Price & Overview
NASDAQ:CRIS • US2312693094
Current stock price
The current stock price of CRIS is 0.5499 USD. Today CRIS is up by 3.17%. In the past month the price decreased by -46.09%. In the past year, price decreased by -55.29%.
CRIS Key Statistics
- Market Cap
- 7.55M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.92
- Dividend Yield
- N/A
CRIS Stock Performance
CRIS Stock Chart
CRIS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CRIS. When comparing the yearly performance of all stocks, CRIS is a bad performer in the overall market: 94.89% of all stocks are doing better.
CRIS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CRIS. Both the profitability and financial health of CRIS have multiple concerns.
CRIS Earnings
On March 19, 2026 CRIS reported an EPS of -0.5 and a revenue of 1.14M. The company missed EPS expectations (-8.93% surprise) and missed revenue expectations (-65.02% surprise).
CRIS Forecast & Estimates
11 analysts have analysed CRIS and the average price target is 14.28 USD. This implies a price increase of 2496.84% is expected in the next year compared to the current price of 0.5499.
For the next year, analysts expect an EPS growth of 37.33% and a revenue growth 7.86% for CRIS
CRIS Groups
Sector & Classification
CRIS Financial Highlights
Over the last trailing twelve months CRIS reported a non-GAAP Earnings per Share(EPS) of -2.92. The EPS increased by 58.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -132.25% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CRIS Ownership
CRIS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRIS
Company Profile
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Company Info
IPO: 2000-08-01
CURIS INC
128 Spring Street, Building C, Suite 500
Lexington MASSACHUSETTS 02421 US
CEO: James Dentzer
Employees: 34
Phone: 13026587581
CURIS INC / CRIS FAQ
What does CRIS do?
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
What is the stock price of CURIS INC today?
The current stock price of CRIS is 0.5499 USD. The price increased by 3.17% in the last trading session.
What is the dividend status of CURIS INC?
CRIS does not pay a dividend.
How is the ChartMill rating for CURIS INC?
CRIS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for CRIS stock?
11 analysts have analysed CRIS and the average price target is 14.28 USD. This implies a price increase of 2496.84% is expected in the next year compared to the current price of 0.5499.
Can you provide the market cap for CURIS INC?
CURIS INC (CRIS) has a market capitalization of 7.55M USD. This makes CRIS a Nano Cap stock.
What is the ownership structure of CURIS INC (CRIS)?
You can find the ownership structure of CURIS INC (CRIS) on the Ownership tab.